{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:01:48Z","timestamp":1784984508988,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijrobp.2025.12.019","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:11:01Z","timestamp":1766535061000},"page":"852-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Compensatory Hypertrophy and Changes of Liver Function After Sequential Transarterial Chemoembolization, Stereotactic Body Radiation Therapy, and Immunotherapy (START-FIT) in Unresectable Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"125","author":[{"given":"Ryo Wan Lung","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Wan Hang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Sik Kwan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Sean Man","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus Wan Yan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ann Shing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Chi Yan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Leung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.019_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0002","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/MS9.0000000000001746","article-title":"Surgical resection for hepatocellular carcinoma: A single-centre's one decade of experience","volume":"86","author":"Syaiful","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0003","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0004","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0005","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1477-2574.2009.00095.x","article-title":"Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database","volume":"11","author":"Aloia","year":"2009","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0006","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/liv.15287","article-title":"Liver growth prediction in ALPPS \u2013 A multicenter analysis from the international ALPPS registry","volume":"42","author":"Lopez-Lopez","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0007","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1091-255X(02)00370-0","article-title":"Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection","volume":"7","author":"Shoup","year":"2003","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0008","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1148\/rg.220050","article-title":"Promoting surgical resection through future liver remnant hypertrophy","volume":"42","author":"Entezari","year":"2022","journal-title":"Radiographics"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0009","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00066-018-1342-y","article-title":"Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer","volume":"194","author":"Rim","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2010.03.025","article-title":"Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy \u2013 Relation to prognosis and liver function","volume":"96","author":"Imada","year":"2010","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ijrobp.2025.12.019_bib0011","first-page":"169","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lanc Gastroen Hepa"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0012","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.semnuclmed.2019.01.009","article-title":"Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma","volume":"49","author":"Gabr","year":"2019","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0014","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jamcollsurg.2012.10.018","article-title":"Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: Toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant","volume":"216","author":"Shindoh","year":"2013","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.01.221","article-title":"Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma","volume":"97","author":"Velec","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0016","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0041-1735530","article-title":"Radiation lobectomy: An overview of concept and applications, technical considerations, outcomes","volume":"38","author":"Entezari","year":"2021","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0017","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11912-021-01075-1","article-title":"Systematic reviews and meta-analyses of portal vein embolization, associated liver partition and portal vein ligation, and radiation lobectomy outcomes in hepatocellular carcinoma patients","volume":"23","author":"Charalel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0019","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00268-016-3662-3","article-title":"ALPPS procedure in insufficient hypertrophy after portal vein embolization (PVE)","volume":"41","author":"Ulmer","year":"2017","journal-title":"World J Surg"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00270-009-9737-x","article-title":"Cardiovascular and Interventional Radiological Society of Europe. Quality improvement for portal vein embolization","volume":"33","author":"Denys","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0021","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.surg.2017.12.027","article-title":"Natural history of portal vein embolization before liver resection: A 23-year analysis of intention-to-treat results","volume":"163","author":"Alvarez","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0022","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0023","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/JHC.S248314","article-title":"Survival outcomes for yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients","volume":"7","author":"Teyateeti","year":"2020","journal-title":"J Hepatocellular Carcinoma"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0024","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00432-020-03443-z","article-title":"Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers","volume":"147","author":"Masthoff","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0026","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1200\/JCO-25-01376","article-title":"Challenges remaining for yttrium-90 radioembolization: The case for standardized dosimetry and comparative local control analyses in liver tumors","volume":"43","author":"Crane","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0028","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0029","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.ijrobp.2019.06.175","article-title":"Individualized hypo-fractionated radiotherapy for advanced hepatocellular carcinoma (HCC): 11-year experience of 172 patients","volume":"105","author":"Wong","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0030","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s12328-024-02030-w","article-title":"Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy","volume":"17","author":"Nakabori","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0031","article-title":"Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy","volume":"39","author":"Wu","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0032","doi-asserted-by":"crossref","first-page":"W812","DOI":"10.2214\/AJR.12.10169","article-title":"Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis","volume":"201","author":"Sanuki","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0033","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2020.01.003","article-title":"Regeneration in acute-on-chronic liver failure \u2013 The phantom lost its camouflage","volume":"72","author":"Engelmann","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0034","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12072-019-09983-y","article-title":"Cellular and functional loss of liver endothelial cells correlates with poor hepatocyte regeneration in acute-on-chronic liver failure","volume":"13","author":"Shubham","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0036","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/hepr.13048","article-title":"Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization","volume":"48","author":"Yasui","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0037","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0038","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000529996","article-title":"Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the phase III IMbrave150 study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0039","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1245\/s10434-009-0454-0","article-title":"Radiation lobectomy: Preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization","volume":"16","author":"Gaba","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jhbp.723","article-title":"Evaluation of segment 4 portal vein embolization added to right portal vein for right hepatic trisectionectomy: A retrospective propensity score-matched study","volume":"27","author":"Ito","year":"2020","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0041","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijsu.2020.01.129","article-title":"Segment 4 occlusion in portal vein embolization increase future liver remnant hypertrophy \u2013 A Scandinavian cohort study","volume":"75","author":"Bj\u00f6rnsson","year":"2020","journal-title":"Int J Surg"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0042","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00270-018-02159-5","article-title":"Segment 2\/3 hypertrophy is greater when right portal vein embolisation is extended to segment 4 in patients with colorectal liver metastases: A retrospective cohort study","volume":"42","author":"Hammond","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0043","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00270-021-02877-3","article-title":"Predictive factors for hypertrophy of the future liver remnant after portal vein embolization: A systematic review","volume":"44","author":"Soykan","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0044","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00259-017-3845-7","article-title":"Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma","volume":"45","author":"Palard","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0045","first-page":"597","article-title":"The human liver after radiation injury. A form of veno-occlusive disease","volume":"48","author":"Jr","year":"1966","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0046","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-K","article-title":"Hepatic toxicity resulting from cancer treatment","volume":"31","author":"Lawrence","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0047","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0167-8140(02)00061-0","article-title":"Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: Clinical manifestation and dosimetric description","volume":"63","author":"Cheng","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0048","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25077-6","article-title":"Prediction of left lobe hypertrophy after right lobe radioembolization of the liver using a clinical data model with external validation","volume":"12","author":"Theysohn","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0049","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41598-022-05672-3","article-title":"A new animal model of atrophy\u2013hypertrophy complex and liver damage following yttrium-90 lobar selective internal radiation therapy in rabbits","volume":"12","author":"P\u00e1ramo","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0050","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0051","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/livers3030029","article-title":"The role of immune cells in liver regeneration","volume":"3","author":"Wen","year":"2023","journal-title":"Livers"},{"key":"10.1016\/j.ijrobp.2025.12.019_bib0052","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1245\/s10434-010-1423-3","article-title":"Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma","volume":"18","author":"Yoo","year":"2011","journal-title":"Ann Surg Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625066076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625066076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:29:46Z","timestamp":1784982586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625066076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0360301625066076"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.019","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compensatory Hypertrophy and Changes of Liver Function After Sequential Transarterial Chemoembolization, Stereotactic Body Radiation Therapy, and Immunotherapy (START-FIT) in Unresectable Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}